Metallothionein

A family of small (6-7 kDa), cysteine-rich proteins that bind heavy metals with extraordinary affinity. Metallothioneins (MTs) are the cell's primary chemical defense against metal toxicity — they sequester cadmium, mercury, lead, and other toxic metals, preventing them from reaching sensitive enzyme targets. But the metallothionein story is more nuanced than simple detoxification. These proteins also regulate the homeostasis of essential metals (zinc and copper), and in cancer biology, their protective role paradoxically enables tumor progression and drug resistance.

Structure and Binding

  • Cysteine content: ~30% of amino acid residues are cysteine, providing abundant thiol (-SH) groups for metal coordination
  • Two domains: Alpha domain binds 4 divalent metal ions; beta domain binds 3 divalent metal ions
  • A single MT molecule can bind 7 zinc or cadmium atoms, or 12 copper(I) atoms
  • Binding hierarchy (affinity): Hg2+ > Cu+ > Cd2+ > Zn2+ — meaning toxic metals displace zinc when they arrive, which is both protective (sequestering the toxicant) and disruptive (liberating zinc)

Dual Role in Metal Homeostasis

Zinc Buffering

Under normal conditions, metallothionein functions as a zinc buffer:

  • Stores zinc in a readily exchangeable form
  • Releases zinc in response to oxidative stress (ROS oxidize MT cysteine residues, liberating bound Zn)
  • Participates in zinc transfer to newly synthesized apoenzymes
  • The MT zinc buffer system interfaces with the broader metal homeostasis network

Cadmium Detoxification

When cadmium enters the cell, MT is the primary defense [1]:

  • Cd2+ displaces Zn2+ from MT due to higher binding affinity
  • Cd-MT complex is thermodynamically stable, reducing free Cd availability
  • MT expression is strongly induced by Cd exposure (positive feedback loop)
  • However, Cd-MT is not permanently inactivated — it is filtered at the renal glomerulus and reabsorbed in proximal tubules, where lysosomal degradation (pH 4.5-5.5) releases free Cd, causing tubular damage. This is the molecular basis of cadmium nephrotoxicity and its connection to chronic kidney disease

Copper Regulation

  • MT binds Cu(I) with high affinity (12 atoms per molecule)
  • Copper displaces zinc from MT due to higher affinity, creating Cu-MT complexes
  • This Cu-Zn competition at MT binding sites contributes to the Cu/Zn ratio distortion seen across cancer and inflammatory conditions
  • Chronic high-dose zinc supplementation induces intestinal MT, which then binds dietary copper, reducing copper absorption — the basis for zinc-induced copper deficiency

The Cancer Paradox

In breast cancer, metallothionein plays a double-edged role [2]:

Protection (Initially)

  • MT sequesters cadmium, reducing its availability to damage DNA, displace zinc from zinc-finger transcription factors, and activate estrogen receptors as a metalloestrogen
  • MT induction is the cell's first-line defense against Cd-mediated genotoxicity

Enabling Progression (Subsequently)

  • Higher MT expression in breast tumors predicts cancer progression and drug resistance
  • MT sequesters platinum-based chemotherapy drugs (cisplatin, carboplatin) via the same thiol-binding mechanism used for cadmium, reducing drug efficacy
  • Cd accumulates preferentially in mammary tissue bound to MT (0.053 ug/g malignant vs 0.02 ug/g normal) — MT enables the accumulation by preventing acute toxicity while permitting chronic estrogenic stimulation
  • MT-mediated zinc release under oxidative stress may activate metalloproteinases and other zinc-dependent enzymes that promote invasion and metastasis

Disease Contexts

Chronic Kidney Disease

Cd-MT complexes undergo renal tubular reabsorption and lysosomal degradation, releasing free Cd in proximal tubule cells. This mechanism makes the kidney the primary chronic target organ for cadmium toxicity and connects MT-mediated "protection" to progressive renal injury.

Autism Spectrum Disorder

Toxic metals (Hg, Cd, Pb) compete with zinc for MT binding. In ASD, where toxic metal burdens are elevated and zinc is depleted, MT capacity may be overwhelmed — leaving both zinc-dependent enzymes unprotected and toxic metals unsequestered.

Neurodegeneration

Brain MT isoforms (MT-I, MT-II, MT-III) regulate zinc and copper availability in neural tissue. MT-III is enriched in the brain and specifically modulates zinc-dependent neurotransmission. Altered MT-III expression in Alzheimer's disease may contribute to the copper/zinc redistribution that drives amyloid-beta-aggregation.

Connections

  • zinc — MT is the primary intracellular zinc buffer
  • copper — Cu displaces Zn from MT; chronic Zn supplementation induces MT to reduce Cu absorption
  • cadmium — MT is the primary Cd detoxification mechanism; Cd-MT paradox in cancer and kidney
  • chronic kidney disease — Cd-MT tubular reabsorption causes nephrotoxicity
  • breast cancer — MT predicts progression and drug resistance
  • metalloestrogen — MT sequestration modulates Cd availability for ER activation
  • metal homeostasis — MT is a core component of cellular metal buffering
  • mis metallation — MT binding hierarchy enables displacement cascades
  • alpha klotho — Cd released from MT in renal tubules suppresses klotho

References (9)

  1. . genchi 2020 cadmium toxicity
  2. . tarhonska 2022 cadmium breast cancer mechanisms
  3. . jaishankar 2014 heavy metal toxicity mechanisms
  4. . rasin 2025 cadmium exposure health review
  5. . rosario 2019 constraint based modelling microbiome cometabolism parkinsons
  6. . rahim 2023 probiotics prebiotics synbiotics asd meta analysis
  7. . saleh 2020 serum trace elements prostate cancer
  8. . blume 2026 metallomics metabolomics metal homeostasis c elegans
  9. . chen 2022 living microorganisms detoxification heavy metals

Related Articles